Case File
efta-01913779DOJ Data Set 10OtherEFTA01913779
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01913779
Pages
2
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
To:
epstein. Jeffrey (jeevacation©gmail.com)(epstein, Jeffrey (jeevacationegmail.com)];
jeevacationajmail.comUeevaeation©gmail.comj
From:
Barrett, Paul S
Sent
Mon 7/28/2014 2:26:25 PM
Subject: Still need
To trade securities:
POA
Suitability
E-consent
To trade derivatives:
Derivatives Approval Form
Bi-Lateral Agreement I and II
ISDA
Paul Barrett I Managing Director I Global Investment Opportunities Group I J.P. Morgan Securities Lit I J.P.
Morgan Private Bank
J.P. Morgan Chase Bank N.A.
NOT AN OFFICIAL CONFIRMATION: For informational purposes only. This report does not represent an
official account of the holdings, balances, or transactions made in your account and is being provided at your
request. Please refer to your monthly account statement for the official record of all of your account activities. For
question, please call your J.P. Morgan representative.
EFTA_R1_00352013
EFTA01913779
In discussion of options and other strategies, results and risks are based solely on hypothetical examples cited;
actual results and risks will vary depending on specific circumstances. Investors are urged to consider carefully
whether option or option-related products in general, as well as the products or strategies discussed herein are
suitable to their needs. In actual transactions, the client's counterparty for OTC derivatives applications is
JPMorgan Chase Bank. N.A.. and affiliates. For a copy of the "Characteristics and Risks of Standardized Options"
booklet, please contact your JPMorgan Advisor.
This email is confidential and subject to important disclaimers and conditions including on offers for the purchase
or sale of securities. accuracy and completeness of information, viruses, confidentiality, legal privilege. and legal
entity disclaimers, available at http://wwwjpmorgan.com/pagestdisclosures/email.
This email is confidential and subject to important disclaimers and conditions including on offers
for the purchase or sale of securities, accuracy and completeness of information, viruses,
confidentiality, legal privilege, and legal entity disclaimers, available at
http://www.jpmorgan.com/pages/disclosures/email.
EFTA_R1_00352014
EFTA01913780
Technical Artifacts (5)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
gmail.comDomain
jeevacationegmail.comSWIFT/BIC
OFFICIALURL
http://www.jpmorgan.com/pages/disclosures/emailURL
http://wwwjpmorgan.com/pagestdisclosures/emailRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.